Nestor Delrosario, MD
Pulmonary Disease · Waipahu, HINPI 1730112160
Payments from drug & device makers
Across 644 payments — averaging $16.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- GSK$1K
- Amarin Pharma, Inc.$1K
- Bayer$769
- Amgen$585
- Astellas Pharma US Inc$581
- plus $4K from 27 others
What the payments were for
- Food & beverage$10,46799%
- Education$1121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 121 | $2,796 |
| GSK | 101 | $1,169 |
| Amarin Pharma, Inc. | 69 | $1,044 |
| Bayer | 46 | $769 |
| Amgen(2 entities) | 55 | $585 |
| Astellas Pharma US Inc | 24 | $581 |
| Novo Nordisk | 43 | $469 |
| Kowa Pharmaceuticals America, Inc. | 30 | $458 |
| Esperion Therapeutics, Inc. | 31 | $413 |
| AbbVie(2 entities) | 17 | $359 |
| Gilead | 24 | $339 |
| Boehringer Ingelheim | 13 | $290 |
| Lilly USA, LLC | 14 | $248 |
| Actelion Pharmaceuticals US, Inc. | 12 | $228 |
| Radius Health, Inc. | 11 | $134 |
| Johnson & Johnson | 5 | $81 |
| Jazz Pharmaceuticals Inc. | 4 | $77 |
| Merck | 3 | $71 |
| Baxter Healthcare | 1 | $58 |
| Insmed, Inc. | 1 | $50 |
| Novartis | 2 | $42 |
| Sarepta Therapeutics, Inc. | 1 | $41 |
| Regeneron Healthcare Solutions, Inc. | 3 | $40 |
| Genentech USA, Inc. | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $35 |
| Harmony Biosciences LLC | 1 | $31 |
| Galt Pharmaceuticals, LLC | 1 | $29 |
| Pfizer | 2 | $25 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Insulet Corporation | 1 | $16 |
| ANI Pharmaceuticals, Inc. | 1 | $13 |
| Smith+Nephew | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,579 in reported general payments places this provider in the 75th percentile of 44 pulmonary disease providers in Hawaii.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 263 | $411,169 |
| UptraviSelexipag | 12 | $286,322 |
| JanuviaSitagliptin Phosphate | 226 | $244,576 |
| FarxigaDapagliflozin Propanediol | 224 | $239,393 |
| JardianceEmpagliflozin | 178 | $223,348 |
| KerendiaFinerenone | 123 | $134,251 |
| Fasenra PenBenralizumab | 20 | $118,190 |
| VascepaIcosapent Ethyl | 116 | $87,971 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $79,798 |
| MounjaroTirzepatide | 44 | $66,036 |
| Ambrisentan | 11 | $58,071 |
| EliquisApixaban | 60 | $54,248 |
| MyrbetriqMirabegron | 54 | $47,663 |
| Tadalafil | 11 | $29,963 |
| XareltoRivaroxaban | 24 | $29,893 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $469 | $440,804286 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $2,796 | $300,199332 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi | $228 | $286,32212 claims |
| MerckJanuvia, Janumet Xr, Janumet | $71 | $278,147249 claims |
| Boehringer IngelheimJardiance, Tradjenta | $290 | $249,194203 claims |
| BayerKerendia | $769 | $134,251123 claims |
| GSKTrelegy Ellipta, Arexvy | $1,169 | $94,290147 claims |
| Lilly USA, LLCMounjaro | $248 | $66,03644 claims |
| PfizerEliquis | $25 | $54,24860 claims |
| Astellas Pharma US IncMyrbetriq | $581 | $47,66354 claims |
| Johnson & JohnsonXarelto | $81 | $29,89324 claims |
| Esperion Therapeutics, Inc.Nexlizet, Nexletol | $413 | $25,43926 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 44 pulmonary disease providers in Hawaii.
Other pulmonary disease in Waipahu
- Magdy MettiasWaipahu$20K
- Takkin LoHonolulu$324K
- Bradley TokeshiHonolulu$107K
- Christopher FiackHonolulu$56K
- Ernie YimHonolulu$20K
- Eric CrawleyHonolulu$17K
- Samuel EvansHonolulu$15K
- George GiacoppeTripler Army Medical Center$14K
- Tad JacksonLihue$14K
- Ronson SatoHonolulu$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.